Real-world use of carfilzomib therapy among patients with existing cardiovascula...
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma pati...
Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma patients ( Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK )
25 Sep 2019
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients wi...
Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2019
Iberdomide in combination with dexamethasone for multiple myeloma
Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA
Iberdomide in combination with dexamethasone for multiple myeloma ( Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA )
25 Sep 2019
First results of the GMMG-CONCEPT trial for multiple myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
First results of the GMMG-CONCEPT trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Sep 2019
What is the role of autologous stem cell transplant in multiple myeloma?
Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical ...
What is the role of autologous stem cell transplant in multiple myeloma? ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )
25 Sep 2019
Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multipl...
Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical ...
Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multiple myeloma ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )
25 Sep 2019
PLEIADES: Daratumumab combinations for multiple myeloma
Dr Ajai Chari - Mount Sinai, New York City, USA
PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )
25 Sep 2019
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multipl...
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
Treatment options for high risk relapsed/refractory multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multip...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019